or Try an Advanced Search...

    Technical Analysis for CVAC - CureVac N.V.

    Grade Last Price % Change Price Change
    F 2.33 0.87% 0.02
    CVAC closed up 0.87 percent on Friday, April 26, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CVAC trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 0.87%
    Lower Bollinger Band Walk Weakness 0.87%
    New 52 Week Low Weakness 0.87%
    Earnings Movers Other 0.87%
    Wide Bands Range Expansion 0.87%
    Lower Bollinger Band Touch Weakness 0.87%
    Older End-of-Day Signals for CVAC ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 15 hours ago
    Down 1% about 18 hours ago
    Lower Bollinger Band Support about 18 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    Up 3% about 19 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CVAC Chart by TradingView
    Basic chart:

    Profile

    CureVac N.V. Description

    CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab

    Is CVAC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript
    Apr 24 CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
    Apr 24 CureVac N.V. 2023 Q4 - Results - Earnings Call Presentation
    Apr 24 CureVac reports Q4 results
    Apr 24 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
    Apr 24 CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
    Apr 24 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
    Apr 24 CureVac to cut costs in restructuring
    Apr 23 CureVac BV FQ4 2023 Earnings Preview
    Apr 23 CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%
    See more CVAC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.36
    52 Week Low 2.215
    Average Volume 790,963
    200-Day Moving Average 5.48
    50-Day Moving Average 3.07
    20-Day Moving Average 2.73
    10-Day Moving Average 2.50
    Average True Range 0.18
    RSI (14) 28.57
    ADX 32.49
    +DI 11.54
    -DI 32.46
    Chandelier Exit (Long, 3 ATRs) 2.66
    Chandelier Exit (Short, 3 ATRs) 2.75
    Upper Bollinger Bands 3.23
    Lower Bollinger Band 2.24
    Percent B (%b) 0.09
    BandWidth 36.30
    MACD Line -0.21
    MACD Signal Line -0.18
    MACD Histogram -0.0269
    Fundamentals Value
    Market Cap 521.74 Million
    Num Shares 224 Million
    EPS -1.58
    Price-to-Earnings (P/E) Ratio -1.47
    Price-to-Sales 18.27
    Price-to-Book 1.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.54
    Resistance 3 (R3) 2.55 2.48 2.51
    Resistance 2 (R2) 2.48 2.43 2.48 2.49
    Resistance 1 (R1) 2.41 2.40 2.45 2.40 2.48
    Pivot Point 2.34 2.34 2.36 2.34 2.34
    Support 1 (S1) 2.27 2.29 2.31 2.26 2.18
    Support 2 (S2) 2.20 2.26 2.20 2.17
    Support 3 (S3) 2.13 2.20 2.16
    Support 4 (S4) 2.12